Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

Authors

Eugene Chung

Published

June 10, 2003

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

Circulation

Topics

DOI

10.1161/01.cir.0000077913.60364.d2

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

Authors

Eugene Chung

Published

June 10, 2003

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

Circulation

Topics

DOI

10.1161/01.cir.0000077913.60364.d2

Paper

Paper

Paper

Paper

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

Supporters

Journal

Topics

DOI

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

Supporters

Journal

Topics

DOI